Agrovet Market Launches Atrevia 360° for Dogs in Bolivia

Agrovet Market brings Atrevia® 360° to Bolivia

Agrovet Market has expanded its companion-animal portfolio in Bolivia through the commercial introduction of Atrevia® 360°, an oral antiparasitic chewable formulation for dogs. The launch was conducted in Santa Cruz de la Sierra by Petmedica®, Agrovet Market’s companion-animal division, in collaboration with local partner Univet SRL.

Agrovet Market confirmed the product presentation and outlined its positioning in the canine parasite-control category. The event reportedly attracted approximately 300 veterinary professionals, including clinicians, practice owners and other animal-health specialists.

The launch adds another product to a market where veterinary teams increasingly need practical options for managing multiple parasite risks. It also illustrates how regional pharmaceutical companies use local distribution partners, technical education and in-person veterinary engagement to support the introduction of new products.

Three active ingredients target internal and external parasites

According to Agrovet Market, Atrevia® 360° combines three active ingredients: fluralaner, moxidectin and praziquantel.

The ingredients have different antiparasitic roles:

• Fluralaner is an isoxazoline ectoparasiticide used against susceptible external parasites, including fleas and ticks.

• Moxidectin is a macrocyclic lactone used against specified susceptible parasites, with the precise coverage dependent on the product’s approved label.

• Praziquantel is an anthelmintic used against susceptible cestodes, including tapeworms.

The combination is positioned to provide broad-spectrum protection against selected external and internal parasites. Agrovet Market describes the product as offering prolonged action of up to three months against certain ectoparasites, alongside activity against specified internal parasites.

That duration should not be interpreted as identical protection against every parasite. The relevant species, treatment intervals, minimum age and weight, contraindications and geographical indications must be checked against the locally authorised product information.

Combining active ingredients can simplify parasite-control routines, but it also places greater importance on appropriate patient selection, correct dosing and veterinary oversight. The product should not be assumed to replace every element of a dog’s parasite-prevention programme.

Palatability and treatment compliance

The company also highlights SmartCap® technology, which it says helps mask bitter flavours and improve voluntary acceptance of the chewable formulation.

Palatability is commercially relevant in companion-animal medicine because treatment effectiveness depends partly on whether owners can administer the prescribed dose correctly and consistently. A formulation that is easier to give may reduce practical barriers for some households.

Agrovet Market reports that technical information and field-study findings were presented at the Bolivian launch. The publicly available launch announcement does not, on its own, provide sufficient detail to independently assess the studies’ design, sample size, comparator products or statistical results. Those details would be needed before making stronger comparative efficacy or safety claims.

Why the Bolivian launch matters

Bolivia’s veterinary market offers a distinct operating environment shaped by geographical diversity, local parasite exposure, distribution access and differences in veterinary-service availability. A product launch in Santa Cruz de la Sierra can provide a platform for professional education and commercial engagement, but it does not establish nationwide market penetration.

Univet’s role is important to the route-to-market strategy. Local distributors can support access to veterinary practices, product information and ongoing engagement with clinicians. For the manufacturer, a partner-led approach can help translate product development into local availability without relying exclusively on direct commercial infrastructure.

Agrovet Market has an established presence in Latin American veterinary markets. Its portfolio spans animal-health categories, while Petmedica focuses on companion-animal products. Atrevia® 360° adds a multi-parasite canine offering to that companion-animal proposition.

Competitive positioning in canine parasite control

The canine antiparasitic category includes products targeting fleas, ticks, mites, heartworm-related risks, intestinal worms and other parasites, with different products covering different combinations. Competitors may use single active ingredients, combinations or distinct dosing schedules.

Atrevia® 360°’s proposition rests on three elements: a combination of active ingredients, an oral chewable format and the company’s stated extended duration against certain external parasites.

For veterinary practitioners, product selection should be driven by the dog’s individual parasite risks, health status, age, weight, concurrent medicines and local product labelling—not by the breadth of a brand’s marketing claims alone.

For distributors and retailers, the launch creates a need for clear training on the product’s approved indications, dose administration, safety information and distinctions between parasite species. Effective communication can help prevent the common commercial problem of presenting a broad-spectrum product as though it covers every parasite or every clinical circumstance.

Outlook

The Bolivia launch represents a concrete step in Agrovet Market’s companion-animal commercial expansion. Its success will depend on local availability, veterinary confidence, clear product education, affordability, patient suitability and repeat use where clinically appropriate.

The wider strategic significance lies in the role of regional animal-health companies in bringing differentiated formulations to local markets through partnerships with distributors and veterinary professionals. Whether Atrevia® 360° gains meaningful share will require evidence from subsequent distribution, sales and adoption data.